logo-loader
RNS
viewReNeuron Group PLC

Result of AGM

/**/ h1{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman","serif";color:windowtext;font-weight:bold;}h2{margin:0cm;margin-bottom:.0001pt;font-size:16.0pt;font-family:"Times New Roman","serif";color:windowtext;font-weight:bold;}h3{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman","serif";color:windowtext;font-weight:bold;}h4{margin:0cm;margin-bottom:.0001pt;text-align:center;font-size:16.0pt;font-family:"Times New Roman","serif";color:windowtext;font-weight:bold;}h5{margin:0cm;margin-bottom:.0001pt;text-align:justify;text-justify:inter-ideograph;font-size:12.0pt;font-family:"Times New Roman","serif";color:windowtext;font-weight:bold;}h6{margin:0cm;margin-bottom:.0001pt;text-align:right;font-size:12.0pt;font-family:"Times New Roman","serif";color:windowtext;font-weight:bold;}p{margin-right:0cm;margin-left:0cm;font-size:12.0pt;font-family:"Times New Roman","serif";color:black;}ol{margin-bottom:0cm;}ul{margin-bottom:0cm;}link{ color: blue } visited{ color: purple } .bc{size:595.3pt 841.9pt;margin:72.0pt 106.25pt 49.65pt 90.0pt;}div.bc{}h1.by{text-indent:117.0pt}span.bz{font-weight:normal}table.cb{margin-left:-5.4pt;border-collapse:collapse}td.bw{width:176.65pt;padding:0cm 5.4pt 0cm 5.4pt}span.bx{font-family:"Calibri","sans-serif"}td.bu{width:211.6pt;padding:0cm 5.4pt 0cm 5.4pt}h3.bv{text-align: right}p.a,li.a,div.a{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman","serif";color:windowtext;} h1.bs{text-align: center}p.cc{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman","serif";color:windowtext;text-align: center}p.cd{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman","serif";color:windowtext;font-weight: bold; text-align: center}p.ce{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman","serif";color:windowtext;text-align:justify;text-justify:inter-ideograph}span.bp{font-family:"Calibri","sans-serif";color:black}p.cf{margin:0cm;margin-bottom:.0001pt;text-autospace:none;font-size:12.0pt;font-family:"Calibri","sans-serif";color:black;text-align:justify;text-justify:inter-ideograph}p.cg{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman","serif";color:windowtext;font-weight: bold; text-align: justify; text-justify: inter-ideograph}table.ch{width:411.1pt}td.bk{width:67.26%;padding:0cm 0cm 0cm 0cm}p.ci{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman","serif";color:windowtext;font-weight: bold} span.bm{font-family:"Calibri","sans-serif"; color:black}td.bi{width:32.74%;padding:0cm 0cm 0cm 0cm}p.cj{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman","serif";color:windowtext;text-align: right}p.ck{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman","serif";color:windowtext;font-weight: bold; margin-right: -104.85pt}p.cl{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman","serif";color:windowtext;font-weight: bold; text-align: right}span.ba{font-family:"Calibri","sans-serif";color:black;}p.cm{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman","serif";color:windowtext;margin-bottom:13.5pt}p.bd{margin-top:0cm;margin-right:0cm;margin-bottom:15.0pt;margin-left: 0cm;text-align:justify;text-justify:inter-ideograph;background:white} /**/
RNS Number : 1409M
ReNeuron Group plc
12 September 2019
 

 

 

12 September 2019

AIM: RENE

 

 

ReNeuron Group plc

("ReNeuron" or the "Company")

 

Result of AGM

 

ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, announces that all resolutions put to shareholders at its Annual General Meeting ("AGM") held earlier today were duly passed.

 

ENDS

 

ENQUIRIES:

 

ReNeuron

 +44 (0)20 3819 8400

Olav Hellebø, Chief Executive Officer


Michael Hunt, Chief Financial Officer


 

Buchanan (UK)

 

+44 (0) 20 7466 5000

Mark Court, Sophie Wills, Tilly Abraham


 

Argot Partners (US)

Stephanie Marks, Claudia Styslinger

 

Stifel Nicolaus Europe Limited

     

  +1 212 600 1902

        

 

 +44 (0) 20 7710 7600

Jonathan Senior, Stewart Wallace, Ben Maddison (NOMAD and Joint Broker)


 

N+1 Singer

 

+44 (0) 20 7496 3000

Aubrey Powell, James Moat, Mia Gardner

(Joint Broker)


 

About ReNeuron

ReNeuron is a global leader in cell-based therapeutics, harnessing its unique stem cell technologies to develop 'off the shelf' stem cell treatments, without the need for immunosuppressive drugs.  The Company's lead clinical-stage candidates are in development for the blindness-causing disease, retinitis pigmentosa, and for disability as a result of stroke.  ReNeuron is also advancing its proprietary exosome technology platform as a potential delivery system for drugs that would otherwise be unable to reach their site of action.  ReNeuron's shares are traded on the London AIM market under the symbol RENE.L.  For further information visit www.reneuron.com.


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
RAGCKBDDKBKDFCD

Quick facts: ReNeuron Group PLC

Price: 147.5

Market: LSE
Market Cap: £46.95 m
Follow

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

ReNeuron signs retinal stem cell exclusivity agreement

ReNeuron Group Plc (LON:RENE) has inked a deal worth up to US$5mln ahead of potentially licensing out its ground-breaking its hRPC retinal stem cell technology and therapeutic programmes. CFO Michael Hunt says they're hoping the exclusivity agreement with an unnamed US-based speciality...

on 11/7/18